Logo image
Current state and novel approaches of antiplatelet therapy
Journal article   Peer reviewed

Current state and novel approaches of antiplatelet therapy

P. Metharom, M.C. Berndt, R.I. Baker and R.K. Andrews
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.35(6), pp.1327-1338
2015
url
Free to Read *No subscription requiredView

Abstract

An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding. Antiplatelet drugs are widely used clinically, either chronically for people at risk of athero/thrombotic disease or to prevent thrombus formation during surgery. However, a subpopulation may be resistant to standard doses, while the platelet targets of these drugs are also critical for the normal hemostatic function of platelets. In this review, we will briefly examine current antiplatelet therapy and existing targets while focusing on new potential approaches for antiplatelet therapy and improved monitoring of effects on platelet reactivity in individuals, ultimately to improve antithrombosis with minimal bleeding. Primary platelet adhesion-signaling receptors, glycoprotein (GP)Ib-IX-V and GPVI, that bind von Willebrand factor/collagen and other prothrombotic factors are not targeted by drugs in clinical use, but they are of particular interest because of their key role in thrombus formation at pathological shear.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.71 Cardiology - Circulation
1.71.193 Acute Myocardial Infarction
Web Of Science research areas
Hematology
Peripheral Vascular Disease
ESI research areas
Clinical Medicine
Logo image